Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05162118
Other study ID # VG161-IIS-201
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 8, 2022
Est. completion date December 22, 2025

Study information

Verified date March 2022
Source Zhejiang University
Contact Tingbo Liang, Doctor
Phone 13967159109
Email liangtingbo@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This is a multicenter, open, single-arm design clinical trial coducted in HSV-seropositive subjects with advanced pancreatic cancer to determine the safety, tolerability and preliminary efficacy of VG161 combined with PD-1 inhibitor (Nivolumab Injection).


Description:

A multicenter, open, single-arm design of clinical trial of VG161 in combined with PD-1 inhibitor (Nivolumab) in the treatment of patients with advanced pancreatic cancer with metastasis. The standard 3 + 3 design was used in the dose-finding study to explore the safety of the combination treatment, determine the recommended safe dose (RP2D) of the combination treatment in the second phase of efficacy study. The first cycle was observed until Day 28, i.e., DLT observation period. In the efficacy investigation trial, Simon two-segment design was used to continue to investigate the preliminary efficacy of the combination at a safe dose.


Recruitment information / eligibility

Status Recruiting
Enrollment 51
Est. completion date December 22, 2025
Est. primary completion date March 22, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Subjects must give informed consent to this study before the trial and voluntarily sign a written informed consent form - Age 18 to 75 years (inclusive), male or female - According to the Guidelines for the Diagnosis and Treatment of Pancreatic Cancer, patients with histologically or cytologically confirmed advanced primary pancreatic ductal adenocarcinoma, acinar cell carcinoma or adenosquamous carcinoma, accompanied by metastasis (TxNxM1), who have failed standard treatment, or have no effective treatment at this stage - The presence of at least one intratumoral injection lesion with the longest diameter (the longest diameter of lymph nodes) greater than or equal to 1.5 cm that is required by the dose volume of the acceptable current dose group, including superficial lesions or deep lesions that can be injected under B ultrasound/CT guidance (such as liver metastases, etc.) - Herpes simplex virus type I (HSV-1) antibody test results (HSV-1IgG or HSV-1IgM) are positive - ECOG performance score 0-1 - The expected survival time is more than 3 months - Adequate organ function: 1) blood routine (No blood transfusion or colony-stimulating factor treatment Within 14 days): ANC = 1.5 × 10^9/L, PLT = 75 × 10^9/L, Hb = 90 g/L, lymphocyte count = 1.5 × 10^9/L (for lymphocyte count 1.0 × 10^9/L to 1.5 × 10^9/L, the investigator judges whether it is necessary); 2) liver function: TBIL = 1.5 × ULN, ALT = 3 × ULN, AST = 3 × ULN (patients with liver metastases can receive ALT = 5 × ULN, AST = 5 × ULN); 3) Child-Pugh score: A-B; 4) renal function: Cr = 1.5 × ULN, and creatinine clearance = 45ml/min (calculated according to CockftGault formula); 5) coagulation function: activated partial thromboplastin time (APTT) = 1.5 × ULN, international normalized ratio (INR) = 1.5 × ULN - Eligible patients of childbearing potential (male and female) must agree to use a reliable method of contraception (hormonal or barrier method or abstinence) during the trial and for at least 90 days after medication; female patients of childbearing age must have a negative blood pregnancy test 7 days before inclusion Exclusion Criteria: - Received chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy (including PD-1/PD-L1 inhibitors) and other anti-tumor drug therapy 4 weeks before the first use of the study drug, oral fluoropyrimidines and small molecule targeted drugs are 2 weeks before the first use of the study drug or within 5 half-lives of the drug (whichever is longer) - Received other unmarketed clinical trial treatment 4 times before the first use of the study drug - Major organ surgery (excluding needle biopsy) or significant trauma 4 times before the first use of study drugs; 4. Patients who have received systemic corticosteroids (prednisone > 10 mg/day or equivalent doses of the same class of drugs) or other immunosuppressive agents within 14 days before the first use of study drugs; except for the following conditions: the use of topical, ocular, intra-articular, intranasal and inhaled corticosteroids; short-term use of corticosteroids for prophylaxis (such as prevention of contrast agent allergy) - Have received vaccination 4 times before the first use of the study drug - The adverse reactions of previous anti-tumor treatment have not recovered to CTCAE 5.0 grade evaluation = 1 (except alopecia and other toxicities that are judged by the investigator to have no safety risk) - Patients with central nervous system or spinal cord malignant tumors or metastases, which are not suitable for enrollment as judged by the investigator - Accompanied by spinal cord compression, which is not suitable for the investigator's judgment - In the period of herpes simplex virus recurrence and infection, and there are corresponding clinical manifestations, such as oral herpes labialis, herpetic keratitis, herpetic dermatitis, genital herpes and so on. 10.Other active uncontrolled infection - History of immunodeficiency, including a positive HIV antibody test - Patients with active hepatitis B or active hepatitis C. (Patients with hepatitis B virus carriers, stable hepatitis B after drug treatment [HBV-DNA negative] and cured hepatitis C [HCV RNA test negative]) were excluded. 13.History of severe cardiovascular disease: 1) arrhythmia requiring clinical intervention; 2) QTc interval > 480 ms; 3) acute coronary syndrome, congestive heart failure, stroke or other grade III and above cardiovascular events within 6 months; 4) New York Heart Association (NYHA) functional classification = II or LVEF < 40%; 5) uncontrolled hypertension (judged by the investigator) - Patients with active or previous autoimmune diseases that may relapse (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); patients with clinically stable autoimmune thyroiditis, autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone, type I diabetes mellitus treated with stable doses of insulin, vitiligo or recovered childhood asthma/allergy, who do not require any intervention in adulthood - Had received immunotherapy and experienced an irAE grade = 3 - Known alcohol or drug dependence - Patients with mental disorders or poor compliance - Women who are pregnant or breastfeeding - The subject has other serious systemic diseases or other reasons that make the subject unsuitable for this clinical study in the opinion of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab
Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.

Locations

Country Name City State
China the First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary MTD MTD (Maximum tolerable dose) 1 month
Primary Occurrence and numbers of DLT (phase 1) Occurence of DLT (Dose Limiting Toxicity) and numbers of DLT 1 month
Primary Occurence and frequence of AE and SAE (phase 1) Occurence and frequence of Adverse Event (AE) and Serious Adverse Event (SAE) (NCI CTCAE 5.0) 24 month
Primary DCR (phase 2) Evaluate Disease Control Rate by RECIST 1.1 24 month
Primary RP2D (phase 1) RP2D (Recommended dose for phase II) 1 month
Secondary DCR (phase 1) Evaluate Disease Control Rate by RECIST 1.1 24 month
Secondary ORR Evaluate Objective Response Rate by RECIST 1.1 24 month
Secondary PFS Evaluate Progression Free Survival by RECIST 1.1 24 month
Secondary PD-1 PD-1 level in peripheral blood T cells 24 month
Secondary Single cell sequencing Single-cell sequencing of tumor biopsy samples 24 month
Secondary Occurence and frequence of AE and SAE (phase 2) Occurence and frequence of Adverse Event (AE) and Serious Adverse Event (SAE) (NCI CTCAE 5.0) 24 month
Secondary CD3+ Concentration of CD3+ 24 month
Secondary CD4+ Concentration of CD4+ 24 month
Secondary CD8+ Concentration of CD8+ 24 month
Secondary CD4+/CD8+ Concentration of CD4+/CD8+ 24 month
Secondary NK Concentration of NK 24 month
Secondary CD19+ Concentration of CD19+ 24 month
Secondary CD56+ Concentration of CD56+ 24 month
Secondary IL-6 Cytokine levels of IL-6 24 month
Secondary TNF-a Cytokine levels of TNF-a 24 month
Secondary IFN-? Cytokine levels of IFN-? 24 month
Secondary CA19-9 Tumor markers of CA19-9 24 month
Secondary CA125 Tumor markers of CA125 24 month
Secondary CEA Tumor markers of CEA 24 month
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Not yet recruiting NCT03662035 - Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer Phase 2
Recruiting NCT05085548 - ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies Phase 1
Recruiting NCT06111274 - A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT04137536 - A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer Phase 1
Completed NCT04617067 - Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT04469556 - Pancreatic Adenocarcinoma Signature Stratification for Treatment Phase 2
Recruiting NCT04104672 - A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Phase 1
Not yet recruiting NCT05100329 - A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer Phase 2
Completed NCT02101580 - Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer Phase 1
Not yet recruiting NCT06329947 - A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD Phase 2
Recruiting NCT02135822 - Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer Phase 2
Recruiting NCT04803851 - Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT03415802 - Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer Phase 2
Recruiting NCT04643405 - APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma Phase 1/Phase 2
Recruiting NCT03889795 - Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors Phase 1
Completed NCT01303172 - A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT06422156 - SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT04931381 - Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer Phase 3
Recruiting NCT04482257 - Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. Phase 1